At the European Society of Cardiology conference on Sunday, Johnson & Johnson (NYSE:JNJ) presented disappointing results from its MARINER study evaluating the use …
Cowen’s Phil Nadeau takes the FDA victory for Portola in bullish stride, betting on broad adoption kicking off next year.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold or wins the regulator’s blessing. …
Oppenheimer’s Jay Olson still sees 106% return potential for PTLA shares after dialing back the price target.
Oppenheimer analyst Jay Olson weighs in on shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) after the drug maker received FDA approval for betrixaban to prevent venous thromboembolism …
By Terry Chrisomalis Valeant Pharmaceuticals Intl Inc On Monday March 21, 2016 shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were halted pre-market before a …
Drug developer and one-time Wall Street pet Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Thursday released top-line results from a phase 3 study of the oral …
Healthcare analysts are weighing in on biotech stocks Portola Pharmaceuticals Inc (NASDAQ:PTLA) and Sophiris Bio Inc (NASDAQ:SPHS), as shares of both companies fell sharply …
